Department Directory

  • Bruce Yacyshyn, MD
  • Professor of Digestive Diseases
  • Academic Office:
    Medical Sciences Building, 7th Floor
    231 Albert Sabin Way
    Cincinnati, OH 670595
  • Clinical Office:
    UC Health Physicians Office - Clifton
    222 Piedmont Ave., 6th Floor
    Cincinnati, OH 45219
  • Phone: 513-558-5244
  • Email: bruce.yacyshyn@uc.edu

    Research/Clinical Interests:

  • Inflammatory Bowel Disease, Irritable Bowel Syndrome, General Gastroenterology.

    Education/Credentials:

  • Bachelor's Degree: University of Alberta, 1980
  • Medical Degree: University of Alberta, 1982
  • Chief Intern : Edmonton General Hospital , 1982
  • Assistant Resident: University of Toronto, Toronto General Hospital , 1984
  • Assistant Resident: University of Toronto, Toronto General Hospital , 1985
  • Senior Resident: University of Toronto, Sunnybrook Medicine Centre , 1986
  • Clinical Fellowship: Washington University School of Medicine, 1987
  • Research Fellowship: Washington University School of Medicine , 1989

Board Certifications & Licenses:

  • Missouri License, 1986
  • Alberta License, 1989
  • Ohio License, 2001
  • British Columbia License, 2006
  • Indiana License, 2008
  • Diplomate in Internal Medicine, American Board of Internal Medicine, 1986
  • Internal Medicine, FRCPC, 1988
  • Gastroenterology, FRCPC, 1989
  • Certificate of Special Competence, Gastroenterology, RCPSC, 1989
  • Certification, Alberta Medical Association, 1989
  • Fellow of the American College of Gastroenterology, 2006
  • Fellow American Gastroenterological Association, 2011

Peer Reviewed Publications (in chronological order):

  • Yacyshyn, Bruce R (2008). (In Press). Adhesion molecule therapeutics in IBD. . Inflammatory Bowel Diseases , 14 Suppl 2 , S279-80.
  • Mant, M. J., Bain, V. G., Maguire, C. G., Murland, K., & Yacyshyn, B. R. (2006). (In Press). Prevalence of occult gastrointestinal bleeding in celiac disease. . Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association , 4 (4) , 451-4.
  • Yacyshyn, B. R., Schievella, A., Sewell, K. L., & Tami, J. A. (2005). (In Press). Gene polymorphisms and serological markers of patients with active Crohn's disease in a clinical trial of antisense to ICAM-1. . Clinical and Experimental Immunology , 141 (1) , 141-7.
  • Yacyshyn, Bruce R (2005). (In Press). Antisense oligonucleotide treatment of inflammatory bowel diseases. . Methods in Molecular Medicine , 106 , 295-305.
  • Yacyshyn, B. R., & Pilarski, L. M. (2003). (In Press). Discussion on the safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. . Gastroenterology , 125 (5) , 1562; author reply 1.
  • Yacyshyn, B. R., Barish, C., Goff, J., Dalke, D., Gaspari, M., Yu, R., Tami, J., Dorr, F. A., & Sewell, K. L. (2002). (In Press). Dose ranging pharmacokinetic trial of high-dose alicaforsen (intercellular adhesion molecule-1 antisense oligodeoxynucleotide) (ISIS 2302) in active Crohn's disease. . Alimentary Pharmacology & Therapeutics , 16 (10) , 1761-70.
  • Bowen-Yacyshyn, M. B., Bennett, C. F., Nation, N., Rayner, D., & Yacyshyn, B. R. (2002). (In Press). Amelioration of chronic and spontaneous intestinal inflammation with an antisense oligonucleotide (ISIS 9125) to intracellular adhesion molecule-1 in the HLA-B27/beta2 microglobulin transgenic rat model. . The Journal of Pharmacology and Experimental Therapeutics , 302 (3) , 908-17.
  • Yacyshyn, B. R., Chey, W. Y., Goff, J., Salzberg, B., Baerg, R., Buchman, A. L., Tami, J., Yu, R., Gibiansky, E., & Shanahan, W. R. (2002). (In Press). Double blind, placebo controlled trial of the remission inducing and steroid sparing properties of an ICAM-1 antisense oligodeoxynucleotide, alicaforsen (ISIS 2302), in active steroid dependent Crohn's disease. . Gut , 51 (1) , 30-6.
  • Yacyshyn, B. R., & Thomson, A. B. R. (2002). (In Press). The clinical importance of proton pump inhibitor pharmacokinetics. . Digestion , 66 (2) , 67-78.
  • Yacyshyn, B. R., & Crooke, S. T. (2001). (In Press). The concept and application of antisense oligonucleotides. . Diseases of the Colon and Rectum , 44 (9) , 1241-3.
  • Yacyshyn, B. R., & Thomson, A. B. (2000). (In Press). Critical review of acid suppression in nonvariceal, acute, uppergastrointestinal bleeding. . Digestive Diseases (Basel, Switzerland) , 18 (3) , 117-28.
  • Chang, Q., Soper, B. D., Yacyshyn, B. R., & Tepperman, B. L. (2000). (In Press). Alterations in protein kinase C isoforms in experimentally-induced colitis in the rat. . Inflammation Research : Official Journal of the European Histamine Research Society ... [et Al.] , 49 (1) , 27-35.
  • Yacyshyn, B. R., & Shanahan, W. R. (1999). (In Press). Making sense of antisense. . Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie , 13 (9) , 745-51.
  • Marcusson, E. G., Yacyshyn, B. R., Shanahan, W. R., & Dean, N. M. (1999). (In Press). Preclinical and clinical pharmacology of antisense oligonucleotides. . Molecular Biotechnology , 12 (1) , 1-11.
  • Vaile, J. H., Meddings, J. B., Yacyshyn, B. R., Russell, A. S., & Maksymowych, W. P. (1999). (In Press). Bowel permeability and CD45RO expression on circulating CD20+ B cells in patients with ankylosing spondylitis and their relatives. . The Journal of Rheumatology , 26 (1) , 128-35.
  • Yacyshyn, B R (1998). (In Press). New biotechnological therapies for Crohn's disease: where are we now? . BioDrugs : Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy , 10 (4) , 301-16.
  • Yacyshyn, B R (1998). (In Press). Drug treatment for Crohn's disease. . Lancet , 352 (9129) , 743.
  • Yacyshyn, B. R., Bowen-Yacyshyn, M. B., Jewell, L., Tami, J. A., Bennett, C. F., Kisner, D. L., & Shanahan, W. R. (1998). (In Press). A placebo-controlled trial of ICAM-1 antisense oligonucleotide in the treatment of Crohn's disease. . Gastroenterology , 114 (6) , 1133-42.
  • Yacyshyn, B. R., Bowen-Yacyshyn, M. B., & Pilarski, L. M. (1996). (In Press). Inhibition by rapamycin of P-glycoprotein 170-mediated export from normal lymphocytes. . Scandinavian Journal of Immunology , 43 (4) , 449-55.
  • Yacyshyn, B. R., & Meddings, J. B. (1995). (In Press). CD45RO expression on circulating CD19+ B cells in Crohn's disease correlates with intestinal permeability. . Gastroenterology , 108 (1) , 132-7.
  • Yacyshyn, B. R., Lazarovits, A., Tsai, V., & Matejko, K. (1994). (In Press). Crohn's disease, ulcerative colitis, and normal intestinal lymphocytes express integrins in dissimilar patterns. . Gastroenterology , 107 (5) , 1364-71.
  • Pilarski, L. M., Yacyshyn, B. R., & Lazarovits, A. I. (1994). (In Press). Analysis of peripheral blood lymphocyte populations and immune function from children exposed to cyclosporine or to azathioprine in utero. . Transplantation , 57 (1) , 133-44.
  • Yacyshyn, B. R., & Pilarski, L. M. (1993). (In Press). Expression of CD45RO on circulating CD19+ B-cells in Crohn's disease. . Gut , 34 (12) , 1698-704.
  • Yacyshyn, B R (1993). (In Press). Activated CD19+ B cell lamina propria lymphocytes in ulcerative colitis. . Immunology and Cell Biology , 71 ( Pt 4) , 265-74.
  • Jensen, G. S., Belch, A. R., Mant, M. J., Ruether, B. A., Yacyshyn, B. R., & Pilarski, L. M. (1993). (In Press). Expression of multiple beta 1 integrins on circulating monoclonal B cells in patients with multiple myeloma. . American Journal of Hematology , 43 (1) , 29-36.
  • Pilarski, L. M., Yacyshyn, B. R., Jensen, G. S., Pruski, E., & Pabst, H. F. (1991). (In Press). Beta 1 integrin (CD29) expression on human postnatal T cell subsets defined by selective CD45 isoform expression. . Journal of Immunology (Baltimore, Md. : 1950) , 147 (3) , 830-7.

    Research Grants:

  • ISIS Pharmaceuticals. Antisense in an animal model of intestinal inflammation
  • Crohn's & Colitis Foundation of Canada (Operating Grant). Multidrug resistance in inflammatory bowel disease
  • University of Alberta Central Research Fund. IBD epithelium induction of integrins on isolated LPMC
  • UAH Special Services Research Committee. MS patients have peripheral blood CD45RO B-cells and increased intestinal permeability
  • ISIS Pharmaceuticals. Antisense to ICAM-1 in HLA-B27 transgenic rats
  • MSI Foundation. CD45RO+ B-cells in inflammatory bowel disease
  • University Hospital Foundation Broad Medical Research Foundation. MRP isoforms in inflammatory bowel disease Exposure to bacterial flora and gut permeability: a mechanistic correlation in the HLA-B27 animal model of IBD.
  • Merck Investigator Initiated Study Program (IISP). Cell mediated Immunity INCDAD
  • IIS 38933 Merck Sharp & Dohme Corp. Cell Mediated Immunity in Recurrent Clostridium Difficile Infection, PI, Active.

Recent Awards/Honors:

  • Finalist. Canada's Top 40 under 40, 1996
  • American Gastroenterological Association Senior Fellowship Research Award, 1989
  • Research Fellow. Alberta Heritage Foundation for Medical Research, 1987,1989
  • Alberta Heritage Foundation for Medical Research Studentship, 1981
  • Dorothy Jean Usher Memorial Summer Research Award, 1980
  • Faculty of Medicine Student Research Competition (First Place), 1979
  • Faculty of Medicine Student Research Competition (First Place), 1980
  • Ciba-Geigy Summer Research Scholarship, 1979
  • Province of Alberta Undergraduate Scholarship, 1977
  • Province of Alberta Undergraduate Scholarship, 1978
  • Edmonton Civic Trust Scholarship, 1976
  • Province of Alberta Undergraduate Scholarship, 1976
CARE/Crawley Building

More Information


For more information on the UC Department of Internal Medicine, please contact us at:

UC Department of Internal Medicine
231 Albert Sabin Way
Medical Sciences Building Room 6065
PO Box 670557
Cincinnati, OH 45267-0557

Phone: 513-558-4231
Fax: 513-558-0852
Email: ucintmed@uc.edu